We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
-18.54%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.69B
AUM Growth
-$959M
Cap. Flow
-$362M
Cap. Flow %
-21.45%
Top 10 Hldgs %
79.99%
Holding
63
New
4
Increased
11
Reduced
6
Closed
17

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$55M
2
ZYME icon
Zymeworks
ZYME
+$30.4M
3
AKRO
Akero Therapeutics
AKRO
+$18.7M
4
BEAM icon
Beam Therapeutics
BEAM
+$13.8M
5
QURE icon
uniQure
QURE
+$8.26M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$129M
2
SWTX
SpringWorks Therapeutics
SWTX
+$56.4M
3
THRD
Third Harmonic Bio
THRD
+$32.7M
4
NMRA icon
Neumora Therapeutics
NMRA
+$22M
5
CRGX
CARGO Therapeutics
CRGX
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
51
Dyne Therapeutics
DYN
$4.15B
– –
-555,644
Closed -$13.1M
FATE icon
52
Fate Therapeutics
FATE
$275M
– –
-3,049,405
Closed -$5.03M
GBIO
53
DELISTED
Generation Bio
GBIO
– –
-204,687
Closed -$2.17M
GLUE icon
54
CALL
Monte Rosa Therapeutics
GLUE
$1.82B
– –
-21,700
Closed -$151K
HOOK
55
DELISTED
HOOKIPA Pharma
HOOK
– –
-388,861
Closed -$782K
KYMR icon
56
Kymera Therapeutics
KYMR
$8.66B
– –
-350,000
Closed -$14.1M
MLTX icon
57
MoonLake Immunotherapeutics
MLTX
$1.56B
– –
-332,522
Closed -$18M
MRSN
58
DELISTED
Mersana Therapeutics
MRSN
– –
-453,120
Closed -$16.2M
NMRA icon
59
Neumora Therapeutics
NMRA
$306M
– –
-2,071,450
Closed -$22M
PFE icon
60
CALL
Pfizer
PFE
$143B
– –
-5,000,000
Closed -$133M
SWTX
61
DELISTED
SpringWorks Therapeutics
SWTX
– –
-1,560,000
Closed -$56.4M
THRD
62
DELISTED
Third Harmonic Bio
THRD
– –
-3,182,444
Closed -$32.7M
ARTV
63
Artiva Biotherapeutics
ARTV
$487M
– –
-41,453
Closed -$418K
1 2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q1 2025 Portfolio in Review

As of Q1 2025, EcoR1 Capital held 63 positions worth $1.69B, down 36% from $2.65B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

EcoR1 Capital withdrew a net $362M in Q1 2025, closing 17 positions and reducing 6 holdings. Its most notable exit was Arvinas, an estimated $129M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

Against the trend, EcoR1 Capital opened a new position in Akero Therapeutics worth $17.8M.

  • EcoR1 Capital's largest Q1 2025 buy was Akero Therapeutics: 440,000 shares worth $17.8M.
  • EcoR1 Capital added most to Sarepta Therapeutics in Q1 2025, an estimated $55M increase.
  • EcoR1 Capital's biggest Q1 2025 reduction was TScan Therapeutics, cutting an estimated $9.38M.
  • EcoR1 Capital fully exited Arvinas in Q1 2025, selling an estimated $129M.
  • EcoR1 Capital's ten largest holdings make up 80% of its $1.69B portfolio in Q1 2025.
  • EcoR1 Capital opened 4 new positions and closed 17 in Q1 2025.
  • EcoR1 Capital's portfolio value fell 36% quarter-over-quarter to $1.69B.

Based on EcoR1 Capital's 13F filing for Q1 2025, filed 15 May 2025.